Earnings summaries and quarterly performance for CLOVER HEALTH INVESTMENTS, CORP. /DE.
Executive leadership at CLOVER HEALTH INVESTMENTS, CORP. /DE.
Andrew Toy
Detailed
Chief Executive Officer
CEO
Brady Priest
Detailed
Chief Executive Officer of Home Care
Conrad Wai
Detailed
Chief Executive Officer of Counterpart Health
Jamie Reynoso
Detailed
Chief Executive Officer of Medicare Advantage
Karen Soares
Detailed
General Counsel and Corporate Secretary
Peter Kuipers
Detailed
Chief Financial Officer
Board of directors at CLOVER HEALTH INVESTMENTS, CORP. /DE.
Research analysts who have asked questions during CLOVER HEALTH INVESTMENTS, CORP. /DE earnings calls.
Matthew Hewitt
Craig-Hallum Capital Group LLC
3 questions for CLOV
Also covers: ACET, APYX, BHST +21 more
Jonathan Yong
UBS
2 questions for CLOV
Also covers: ALHC, EHTH, OSCR
Jonathan Young
Cantor Fitzgerald
2 questions for CLOV
Also covers: BCS
John French
Leerink Partners
1 question for CLOV
John Pinney
Canaccord Genuity Group Inc.
1 question for CLOV
Also covers: AHCO, HSTM, QIPT
Richard Close
Canaccord Genuity Group
1 question for CLOV
Also covers: ACCD, AHCO, DCGO +15 more
Recent press releases and 8-K filings for CLOV.
Clover Health Discusses Growth, Profitability Outlook, and Technology at Citi Global Healthcare Conference
CLOV
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Clover Health reported 33% year-to-date membership growth as of September 30, 2025, and $45 million in year-to-date adjusted EBITDA.
- The company anticipates achieving GAAP net income profitability for fiscal 2026.
- Its proprietary Clover Assistant technology significantly improves the Medical Cost Ratio (MCR) by 700 basis points from year one to year two, and an additional 700 basis points from year two to year three.
- New members incur a contribution profit loss of approximately $110 per member per month (PMPM), while returning members generate a profit of $217 PMPM.
- For 2026, Clover Health expects roughly similar growth in new members and anticipates financial tailwinds from a four-star payment year, which translates to almost a 5% increase to the top line.
2 days ago
Clover Health Reports Strong Membership Growth and Targets 2026 GAAP Net Income Profitability
CLOV
Revenue Acceleration/Inflection
Guidance Update
New Projects/Investments
- Clover Health reported 33% year-to-date membership growth and $45 million in year-to-date Adjusted EBITDA as of September 30, 2025, and anticipates achieving GAAP net income profitability for fiscal 2026.
- The company's proprietary AI-powered Clover Assistant technology contributes to a medical cost ratio (MCR) improvement of approximately 700 basis points from year one to year two for returning members, and an additional 700 basis points from year two to year three, totaling a 1,400 basis point improvement from year one.
- New members typically result in a contribution profit loss of about $110 per member per month (PMPM), while returning members generate approximately $217 PMPM in profit, with both figures expected to improve in 2026.
- Clover Health will benefit from a four-star payment year in 2026, which is projected to provide an almost 5% increase to the top line.
2 days ago
Clover Health Reports Strong 3Q YTD 2025 Financials and Projects FY26 GAAP Net Income
CLOV
Earnings
Guidance Update
New Projects/Investments
- Clover Health reported strong financial performance for 3Q YTD 2025, with Adjusted EBITDA of $45 million and Adjusted Net Income of $44 million, alongside a 35% year-over-year increase in Medicare Advantage (MA) membership and a 39% year-over-year rise in Insurance revenue.
- The company projects achieving full-year GAAP Net Income and increasing Adjusted EBITDA profitability in 2026, driven by strong retention and the improving performance of its larger, profitable returning member cohort.
- Its proprietary AI-powered Clover Assistant technology is correlated with improved patient health outcomes, including earlier diagnosis of chronic diseases (e.g., ~36 months earlier for Diabetes, ~18 months earlier for Chronic Kidney Disease) and reduced hospitalizations (e.g., 18% lower for Congestive Heart Failure, 15% lower for COPD).
- Clover Health is expanding its reach by commercializing its Clover Assistant technology platform via the Counterpart Health subsidiary, aiming to introduce new SaaS and tech-enabled services revenue streams and extend its care model to a broader market.
4 days ago
Clover Health Investments, Corp. Discusses Q3 2025 Performance and 2026 Outlook
CLOV
Earnings
Guidance Update
New Projects/Investments
- Clover Health experienced medical cost pressures in Q3 2025 due to elevated utilization across all cohorts, particularly new members, though the year-to-date underlying incurred Part C medical cost trend was 4% year-over-year (excluding pharmacy) while absorbing 35% new membership growth.
- The company anticipates achieving full-year GAAP Net Income profitability in 2026, supported by a 4 Star payment year, favorable Part C rate updates, higher Part D Direct Subsidy payments, and strong retention of a larger base of profitable returning members.
- Clover's overall Star Rating was impacted by low scores in pharmacy-specific measures and member experience surveys, despite its PPO plans ranking number one in the nation on HEDIS clinical quality measures with a score of 4.72.
- Clover Assistant's capabilities have strengthened with new AI-driven features, and its third-party offering, Counterpart Health, is showing strong momentum and is expected to become an equally profitable business over time.
Nov 12, 2025, 1:30 PM
Clover Health Discusses 2025 Performance and 2026 Outlook at UBS Global Healthcare Conference
CLOV
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Clover Health projects over 30% (33%) membership growth this year, with revenue up close to 40%, achieving $45 million in year-to-date EBITDA. The company expects to achieve GAAP net income positivity in fiscal 2026.
- The AI-enabled Clover Assistant technology is central to their model, driving earlier diagnoses and significantly lower hospital admissions, and has contributed to the company being ranked #1 in the nation for PPO plans on clinical quality for the second consecutive year.
- New members, comprising 26% of year-to-date growth, are initially loss-making (contribution profit of -$110 PMPM), but profitability improves significantly as they mature, with MCR/BER improving by 700 basis points from year one to year two and another 700 basis points from year two to year three.
- Looking to 2026, Clover Health anticipates tailwinds including a shift from a 3.5-star to a 4-star payment year (adding ~5% to top line), a voluntary retention rate above 90%, and ongoing SG&A optimization.
Nov 11, 2025, 4:00 PM
Clover Health Updates on 3Q YTD 2025 Performance and FY25/FY26 Outlook
CLOV
Earnings
Guidance Update
New Projects/Investments
- Clover Health reported 3Q YTD 2025 Adjusted EBITDA of $45 million and Adjusted Net income of $44 million, with Medicare Advantage (MA) membership growing 35% year-over-year and Insurance revenue up 39% year-over-year.
- The company updated its FY25 Adjusted EBITDA guidance to $15 million and expects to achieve full-year GAAP Net income in FY26.
- Clover Health's PPO plans achieved a 4.0 Star Rating for Payment Year 2026, positioning the company for continued growth and profitability expansion.
- The Clover Assistant (CA) technology has demonstrated improved patient health outcomes, including earlier diagnosis for diabetes and chronic kidney disease, and lower hospitalizations for CHF and COPD, contributing to top-performing HEDIS measures.
- The company anticipates FY25 average MA membership guidance of ~107K, up from ~81K in FY24, driven by strong returning member cohort performance and the commercialization of its CA tech platform via Counterpart Health.
Nov 11, 2025, 4:00 PM
Clover Health Announces Q3 2025 Results and Updates Full-Year 2025 Guidance
CLOV
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Clover Health reported Q3 2025 Medicare Advantage membership of 109,226, an increase of 35% year-over-year, with Insurance revenue growing 49% year-over-year to $479 million.
- For Q3 2025, the company achieved Adjusted EBITDA and Adjusted Net income of $2 million each, despite a GAAP Net loss of ($24 million). Year-to-date Q3 2025, Adjusted EBITDA was $45 million and Adjusted Net income was $44 million.
- The company updated its full-year 2025 guidance, revising Adjusted EBITDA and Adjusted Net Income downwards to a range of $15 million - $30 million (from $50 million - $70 million previously). Insurance Revenue guidance was narrowed to $1.85 billion - $1.88 billion, and Average Medicare Advantage Membership was increased to 106,000 - 108,000.
- Clover Health anticipates achieving full-year GAAP Net income in 2026 and expects above-market growth and profitability expansion, benefiting from a projected 4.0 Star payment year in 2026.
Nov 4, 2025, 10:00 PM
Clover Health Reports Q3 2025 Results and Updates Full-Year Guidance
CLOV
Earnings
Guidance Update
Profit Warning
- Clover Health reported Q3 2025 Medicare Advantage membership growth of 35% year-over-year to over 109,000 members, with insurance revenue increasing 49% year-over-year to $479 million. Year-to-date, the company achieved positive adjusted EBITDA of $45 million and adjusted net income of $44 million.
- The company lowered its full-year 2025 adjusted EBITDA and adjusted net income guidance to between $15 million and $30 million, primarily due to a higher proportion of new members and increased utilization trends. The insurance BER guidance was updated to 90% to 91%.
- Clover Health received a three and a half star rating for the 2026 ratings year, which was below its aspiration. However, its Clover Assistant technology contributed to a HEDIS score of 4.72 for its PPO plans, making it the highest-performing PPO in the country on HEDIS measures.
- The company anticipates a meaningful increase in profitability in 2026, driven by strong returning member retention, improved cohort economics, a four-star payment year for PPO plans, and enhanced Clover Assistant capabilities.
Nov 4, 2025, 10:00 PM
Clover Health Reports Third Quarter 2025 Results and Updates Full Year Guidance
CLOV
Earnings
Guidance Update
Revenue Acceleration/Inflection
- For the third quarter of 2025, Clover Health reported Total revenues of $497 million, a 50% increase year-over-year, and Medicare Advantage membership of 109,226, up 35% year-over-year. The company achieved Adjusted EBITDA of $2 million and Adjusted Net income of $2 million for the quarter.
- Year-to-date through Q3 2025, Clover Health generated positive Adjusted EBITDA of $45 million and Adjusted Net Income of $44 million.
- Clover Health increased its Full Year 2025 Guidance, now expecting Average Medicare Advantage membership between 106,000 and 108,000, Insurance revenue between $1.850 billion and $1.880 billion, and Adjusted EBITDA profitability between $15 million and $30 million.
- The company anticipates achieving full-year GAAP Net Income in 2026, supported by a 4.0 Star payment year, favorable CMS rate updates, increased Part D direct subsidy, and continued cost efficiency initiatives.
Nov 4, 2025, 9:08 PM
Clover Health Announces 2026 Medicare Advantage Offerings
CLOV
Product Launch
New Projects/Investments
- Clover Health announced its 2026 Medicare Advantage offerings, reinforcing its leadership in affordable, high-choice PPO plans.
- The company ensures 100% of its members will have stable or improved benefits for 2026, including $0 to low monthly plan premium MAPD PPOs and $0 monthly plan premium MA only plans.
- These enhanced benefits are underpinned by the AI-powered Clover Assistant platform, which has contributed to a 32% year-over-year growth in MA members.
- The 2026 Annual Enrollment Period runs from October 15 to December 7, 2025, with plans accessible to 5.2 million Medicare-eligible beneficiaries across 203 counties in 5 states.
Oct 15, 2025, 12:30 PM
Quarterly earnings call transcripts for CLOVER HEALTH INVESTMENTS, CORP. /DE.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more